Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities

by AlShaibani, Alfadel , Alfraih, Feras , Alzahrani, Hazzaa , Alsharif, Fahad , Hassanein, Mona , Aljurf, Mahmoud , Fakih, Riad El , Ahmed, Syed , Rasheed, Walid , Chaudhri, Naeem , Elhassan, Tusneem , Alhayli, Saud , Alahmari, Ali , Hashmi, Shahrukh , Shaheen, Marwan , Hanbali, Amr , Almohareb, Fahad , Ahmed, Shad

in Transplant and Cellular Therapy

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities

in Transplant and Cellular Therapy

2021

Confirm

Do you wish to request the book?

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities

in Transplant and Cellular Therapy

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities

AlShaibani, Alfadel,

Alfraih, Feras,

Alzahrani, Hazzaa,

Alsharif, Fahad,

Hassanein, Mona,

Aljurf, Mahmoud,

Fakih, Riad El,

Ahmed, Syed,

Rasheed, Walid,

Chaudhri, Naeem,

Elhassan, Tusneem,

Alhayli, Saud,

Alahmari, Ali,

Hashmi, Shahrukh,

Shaheen, Marwan,

Hanbali, Amr,

Almohareb, Fahad,

Ahmed, Shad

2021

Overview

Secondary acute myeloid leukemia (sAML) includes AML as a complication of an antecedent hematological disorder or a therapy‐related AML. Large registry‐based data identified sAML as an independent poor‐outcome type of AML post allogeneic hematopoietic cell transplantation (allo‐HCT). In our study, we tried to define factors affecting outcomes of sAML post allo‐HCT, and identify patients with sAML who may truly benefit from allo‐HCT. We retrospectively analyzed the data of 64 patients aged (14‐61 years) with sAML who received allo‐HCT between September 2010 and February 2018 at our institute. Most of the patients were transplanted from matched related donors (MRD; 54, 84.4%). Our results showed that poor‐risk cytogenetics were identified in 31 patients (48.4%), and their presence was an indicator of poor overall survival (OS) and disease‐free survival (DFS; P‐value = .009, and .004, respectively). The cumulative incidence of chronic graft‐versus‐host disease (cGVHD) was significantly lower in sAML patients with poor‐risk cytogenetics (P‐value = .003) resulting in a high risk of death without cGVHD in this group of patients (P‐value = .02). Besides, GVHD relapse‐free survival (GRFS) analysis showed that most of our studied patients experienced either relapse or debilitating grade II‐IV cGVHD in the first 2 years post allo‐HCT. We conclude that sAML patients with poor‐risk cytogenetics have a significantly lower DFS post allo‐HCT with a high risk of death without active cGVHD.

Share this book

Add to My Shelf

Publisher

John Wiley and Sons Inc,Wiley

Subject

Transplant and Cellular Therapy